Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation for MET-Mutated Advanced Non-Small Cell Lung Cancer
Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma
Shots:
- The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology
- The BT designation is granted to serious or life-threatening disease therapies demonstrate a substantial improvement over existing therapies on one or more significant preliminary research endpoints
- Capmatinib (INC280) is an oral potent and selective MET inhibitor with expected regulatory submission in Q4’19. In 2009, Novartis signed an exclusive development and commercialization agreement with Incyte for Capmatinib
Click here to read full press release/ article | Ref: Novartis | Image: Wall Street Journal